TSM74
Solid and Hematological Cancers (via XPO1 degradation)
Pre-clinicalActive
Key Facts
Indication
Solid and Hematological Cancers (via XPO1 degradation)
Phase
Pre-clinical
Status
Active
Company
About Telo Therapeutics
Telo Therapeutics is a private, preclinical-stage biotech focused on oncology, leveraging targeted protein degradation to enhance nuclear transport inhibition. Its lead candidate, TSM74, is a novel, orally bioavailable degrader of XPO1 designed to overcome the toxicity limitations of existing covalent inhibitors. The company is incubated at MBC Biolabs and has received support from investors like the MIF and recognition such as a Servier Golden Ticket, positioning it to advance its pipeline for solid and hematological malignancies.
View full company profile